Y2641, a tetrahydro beta-carboline derivative, is an orally active dual inhibitor of RANKL and TNF-alpha, with Kd values of 3.984 µM and 18.59 µM respectively. It suppresses RANKL-induced osteoclastogenesis and exhibits anti-inflammatory and cartilage-protective properties. Y2641 is applicable in osteoarthritis research.
Target-Kategorie:
TNF|||RANKL/RANK
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
